Oridonin, R. rubescens

A cell-permeable diterpenoid compound that possesses anti NF-κB activity and displays antiproliferative (ED₅₀ = ~ 2.7 µg/ml in lymphoid malignant cells) and antiangiogenic properties (significantly inhibits network formation of HMEC-1 cells at 2.5 µg/ml). Reported to affect DNA synthesis, induce apoptosis and initiate cell cycle arrest. Shown to efficiently block both TNF-α and LPS-induced NF-κB activity in Jurkat and in RAW264.7 murine macrophages, and inhibit p65 NF-κB transcriptional activity (IC₅₀ = ~ 5 µg/ml in MT-1 cells) by disrupting NF-κB DNA-binding activity without interfering with its nuclear translocation.

A cell-permeable inhibitor of NF-κB activity that displays antiproliferative (ED₅₀ ~ 2.7 µg/ml in lymphoid malignant cells) and antiangiogenic properties (significantly inhibits network formation of HMEC-1 cells at 2.5 µg/ml). Reported to affect DNA synthesis, induce apoptosis, and initiate cell cycle arrest. Shown to efficiently block both TNF-α and LPS-induced NF-κB activity in Jurkat and in RAW264.7 murine macrophages. Also inhibits p65 NF-κB transcriptional activity (IC₅₀ ~5 µg/ml in MT-1 cells) by disrupting NF-κB DNA-binding activity without interfering with its nuclear translocation.

Cell permeable: yes

Primary Target
NF-κB transcriptional activity

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 5 µg/ml inhibiting p65 NF-κB transcriptional activity in MT-1 cells

Packaged under inert gas

Toxicity: Standard Handling (A)

Use only fresh DMSO for reconstitution.

Ikezoe, T., et al. 2005. Mol. Cancer Ther.4, 578.
Meade-Tollin, L.C., et al. 2004. J. Nat. Prod.67, 2.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany